Navigation Links
Nabriva Therapeutics Announces Appointment of New CEO
Date:7/2/2008

y available pleuromutilin which is first in class and has significant market potential in multiple indications (eg. SSSI & CAP). All of Nabriva's programs are derived from compounds generated in-house through discovery activity and the company maintains an ongoing effort in medicinal chemistry.

The Company was founded in January 2006 as a spin-out of Sandoz GmbH Kundl. The spin-out was led by Nomura Phase4 Ventures with a Series A financing of EUR42 million with a syndicate that included HBM Partners, GLSV, The Wellcome Trust and Novartis Venture Fund.

Contacts:

Claudia Karner,

Tel: +43(0)1-74093-1240,

e-mail: claudia.karner@nabriva.com


'/>"/>
SOURCE Nabriva Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pearl Therapeutics Closes $18 Million Financing Round Led By Committed Investors
2. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
3. Joseph B. Bolen, Ph.D. from Millennium to Conference Chair Cancer Sessions at IBCs Drug Discovery & Development of Innovative Therapeutics Conference
4. Tobira Therapeutics Inc. Announces Senior Management Team
5. Duska Therapeutics Obtains Standard & Poors Listing
6. Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics
7. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
8. Sirion Therapeutics Announces FDA Approval of Durezol(TM) for Treatment of Postoperative Ocular Inflammation and Pain
9. Commercial Launch of Lexiscan(TM) (Regadenoson) Injection Triggers $10 Million Milestone Payment from TPG-Axon Capital to CV Therapeutics
10. Barrier Therapeutics to Merge Into Stiefel Laboratories
11. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Proove Biosciences , the commercial and research ... new genetic test built upon research from their published ... will provide physicians with an objective way to understand ... stratified between individuals. With this new test, physicians will ... genetic predisposition that will affect their pain tolerance. , ...
(Date:9/30/2014)...  RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" ... a Canadian Patent for Inhibition or Reversal of ... claims using thymosin beta 4, various fragments and ... purposes.  The patent will expire in 2021. ... ) RegeneRx is focused on ...
(Date:9/30/2014)... 2014 Fast, semi-automatic creation ... in documents ChemAxon , a ... services for life science research, launches ChemCurator, an ... structures from documents. Markush structures are ... generating and understanding Markush structures is a difficult ...
(Date:9/30/2014)... OriginOil Inc. (OTC/QB: OOIL), developer of Electro ... up large quantities of water, announced today that in ... the launch of the company's CLEAN-FRACâ„¢ industrial grade demonstrator ... STW Resources . , Immediately upon startup, the ... and achieved a 99.8% reduction in Turbidity on flowback ...
Breaking Biology Technology:Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2OriginOil, Inc. Report to Shareholders: Blue Gold in West Texas 2
... Area Technical College is launching a major effort to ... colleges and high schools. The initiative will feature new ... better prepare qualified technicians to work in the fast ... Foundation (NSF) grant - the second such grant MATC ...
... - Alfalight, Inc. , a Madison-based manufacturer ... markets, has been awarded $1.4 million in funding for ... program, sponsored by the Defense Advanced Research Projects ... is to increase a laser's power conversion efficiency -- ...
... Days of summer. Business slows. Indeed, in Europe, where I ... of suspended animation that will last until the first of ... attention. Work's grasp weakens. , ,Or does it? , ,After ... Monday morning mountain in my inbox and a to-do list ...
Cached Biology Technology:Alfalight garners $1.4 million defense funding for diode program 2Leaving it all behind 2
(Date:9/30/2014)... environment on Earth, but when the climate changes and ... limit. The amount of time needed to adjust to ... cope in the future, reveals a new study from ... scientific journal Proceedings of the Royal Society B ... levels of greenhouse gases in the atmosphere. The greenhouse ...
(Date:9/30/2014)... goes wrong with your muscles because of age, disease or ... is. That,s where a new research report published in the ... comes in. In the report, a team of scientists ... help scientists "see" which genes are active in an organ ... activity and that men have approximately 400 more active genes ...
(Date:9/30/2014)... 30, 2014) People who suffer from asthma may ... control their asthma besides properly taking medications and avoiding ... in the Annals of Allergy, Asthma and Immunology ... Allergy, Asthma and Immunology (ACAAI), asthma sufferers can learn ... The woman described in the Annals article improved her ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Scientists identify which genes are active in muscles of men and women 2Asthma symptoms kicking up? Check your exposure to air pollution 2
... HARBOR, N.Y. Many proteins do not function ... associate to form larger structures called protein complexes. ... ( www.cshprotocols.org/TOCs/toc5_09.dtl ) features a set of methods ... An additional featured article details the generation of viral ...
... Society (ACS) Weekly PressPac from the Office of ... peer-reviewed journals and Chemical & Engineering News ... American Chemical Society as the source for this ... ARTICLE #1 FOR IMMEDIATE RELEASE Gene ...
... the introduction of genetic material into a patient,s cells resulting ... years, it has been shown that gene therapy is a ... for which there is no attractive alternative therapy. Gene ... other diseases that affect heart, brain and even for cancer. ...
Cached Biology News:Protein analysis methods, viral vectors featured in Cold Spring Harbor Protocols 2American Chemical Society's weekly PressPac -- April 29, 2009 2American Chemical Society's weekly PressPac -- April 29, 2009 3American Chemical Society's weekly PressPac -- April 29, 2009 4American Chemical Society's weekly PressPac -- April 29, 2009 5American Chemical Society's weekly PressPac -- April 29, 2009 6Moving gene therapy forward with mobile DNA 2
SHEEP ANTI FLECAINIDE...
MOUSE ANTI HUMAN B-CELLS (FMC7):FITC Immunogen: HRIK cells - Human B-Lymphoblastoid line...
... are ideal for use in refrigerators, freezers, or liquid ... vibrant colors allow for color coding to project, user, ... drainage or promote cool air circulation. Supplied with 10 ... tubes. Box dimensions: 13 x 13 x ...
RABBIT ANTI BACTERIAL HISTIDASE...
Biology Products: